Axsome Therapeutics AXSM Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's investing cash flow?
- Axsome Therapeutics (AXSM) reported investing cash flow of -$121K in Q1 2026.
- How has Axsome Therapeutics's investing cash flow changed year-over-year?
- Axsome Therapeutics's investing cash flow increased by 64.2% year-over-year, from -$338K to -$121K.
- What is the long-term trend for Axsome Therapeutics's investing cash flow?
- Over 4 years (2021 to 2025), Axsome Therapeutics's investing cash flow has grown at a 11.7% compound annual growth rate (CAGR), from -$308K to -$480K.
- What does investing cash flow mean?
- The net cash used for or generated by long-term investments and asset purchases.
- How do you interpret investing cash flow?
- Negative values typically indicate active investment in growth or infrastructure, while positive values may indicate asset divestitures or the maturity of investment portfolios.
- How does investing cash flow compare across companies?
- Standard financial statement line item; reflects the company's strategy regarding internal infrastructure versus external investment.